Sefunda - Immediate Informed Diagnostics

The Mission - why we do what we do.

Sefunda is on a mission to make rapid PCR testing an accessible standard for everybody. To date most infectious diseases are treated empirically, meaning a broad-spectrum antibiotic or a combination regimen is prescribed covering multiple possible pathogens. This practice can not only lead to poor outcomes and severe side effects, over-treatment also contributes to our path into a post-antibiotic world. The gold standard for evidence-based treatment is elaborate lab testing including molecular testing and microbiological culture, which is costly and time consuming. If done at all, treatment is still started before results are available, underutilizing the potential of diagnostics. Sefunda takes up the banner to democratize patient tailored medicine by filling a blank between cost prohibitive lab workup and empiric treatment. We are developing a fully integrated rapid PCR platform delivering just the right amount of actionable information on the spot. With time to correct treatment and economic accessibility being fundamental to success, enough information is enough!

“Perfection is achieved, not when there is nothing more to add, but when there is nothing left to take away.” ― Antoine de Saint-Exupéry

The Urgency - what we do first.

Chlamydia and Gonorrhea are the most common notifiable infectious diseases in the US.

Both, chlamydia and gonorrhea, can cause severe reproductive complications and co-infection can lead to a higher transmission rate of HIV. Rapid detection and prompt treatment of patients and partners is imperative to prevent spreading. One of the most urgent global public health concerns is the emergence of extensively drug-resistant gonorrhea. Over the last century gonorrhea has developed resistance to almost every antimicrobial used for its treatment. Today Ceftriaxone (CRO), as the one last resort option Over the last century gonorrhea has developed resistance to almost every antimicrobial used for its treatment. Today ceftriaxone (CRO), as the one last resort option, is recommended as mono-therapy. As more and more strains resistant to this third-generation cephalosporin are emerging, it is only a matter of time until they take over and render some gonorrhea infections untreatable. CRO is administered as an intramuscular injection which usually requires an additional visit to the doctor. Orally administered ciprofloxacin (CIP) has been successfully used for gonorrhea treatment for decades. However, in 2007 WHO recommended against its use due to increasing resistance. While precautions against broad use of CIP are necessary and important, 70-80% of today’s infections in the US are still susceptible to CIP. Sefunda`s CT/NG + R/LGV test provides antimicrobial resistance information immediately together with the positive test result. This information can help providers decide on a safe, effective, and more patient acceptable treatment and has the potential to spare valuable last line treatment to help delay the spread of untreatable pan-resistant gonorrhea.

Inappropriate treatment can also occur if an LGV infection is not recognized. LGV is a Chlamydia sub-type with increased virulence causing more invasive infection of the lymph system compared to CT non-LGV infections. LGV requires a more rigorous treatment regimen but molecular testing to discriminate LGV from non-LGV infections is generally not done.

"Without diagnostics, medicine is blind." - Alain Mérieux

The Benefit - where are we going.

Although desired, Patient tailored treatment is not widely implemented yet. The greatest barrier for achieving it today are economic constraints. Sefunda is taking one step further towards this vision by bridging the gap between cost intense and time-consuming lab testing and empiric treatment. We provide actionable information right at the bedside, the emergency department, private practice or the local pharmacy.

AMR awareness.

The Concept - what we do right.

A real time Diagnostics Platform.

Sefunda simplifies treatment decision. We provide you with diagnostic evidence in under 30 minutes, before the patient leaves the office, right at the point of consultation and care. Our rapid PCR platform, with its small footprint and intuitive design, is placed right where treatment decisions take place. The single use, pre-loaded test cartridge contains our patented assay chemistry and can be stored at room temperature. After sample transfer the cartridge is placed into the receiver slot of the instrument to start the testing process. With only the essential clicks on the touch screen and the integrated barcode scanner, patient data can be entered to seamlessly integrate in the existing information system. You save time when it is needed elsewhere, increase confidence in your decisions and retain revenue for testing in your own office.

The Team.

Board of Directors.

Investors Relations

Sefunda is seeking partnership for investments and network building. We are open for discussion concerning amount, future ownership and pricing.

Interested? Feel free to call or write an email.